Linda Powers was Appointed as Chief Executive Officer at Northwest-Biotherapeutics

Date of management change: January 15, 2008 

What Happened?

Bethesda, MD-based Northwest-Biotherapeutics Appointed Linda Powers as Chief Executive Officer

 

About the Company

NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio`s proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company`s lead product, DCVax-L, is currently in a 348-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. The Company`s second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers. The Company has also conducted a Phase I/II trial with DCVax for late stage ovarian cancer together with the University of Pennsylvania. The Company previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.

 

About the Person

Linda Powers is Chief Executive Officer  at Northwest Biotherapeutics. Previously, Linda held various senior HR leadership roles in the industry.

 

Info Source

News

 
 

Other IT executives who recently changed jobs as well: Juskiw Joan, Marangwanda Shami, Devalle Diego, Calaiaro Pat, Bellerive Amy, Rowe Christine, Kathuria Shivani, Severance Steve, Fass Michael, Bush Stephanie, Simpson Mary

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.